Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotie Therapies has initiated a randomized, double-blind, placebo-controlled Phase 2b study investiagting SYN115 in parkinson's disease (PD).
Subscribe to our email newsletter
SYN115 is an orally bioavailable, potent and selective adenosine A2a receptor antagonist, which enters the brain and modulates regions associated with motor and non-motor function.
Biotie obtained development and commercialization rights to SYN115 from Roche in 2007 for selected diseases of the central nervous system and has an option to rights for development in all indications.
The trail aims to establish the efficacy and safety of SYN115 in reducing the mean time spent in the ‘off’ state over a 12 week treatment period.
In the trial, the company will investigate four doses of SYN115 versus placebo as adjunctive therapy in 400 levodopa-treated PD patients with end of dose wearing off.
Biotie president and CEO Timo Veromaa said SYN115 is the lead product coming from the recent acquisition of Synosia and they are very pleased to advance this candidate into late-stage clinical development.
"Despite the availability of treatments for PD, there remains a significant unmet medical need for therapies with an alternative mechanism of action and SYN115 could be the first drug with a novel mechanism of action in PD for a generation," Veromaa said.